• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Intertek launches cGMP cell based assay services

Intertek launches cGMP cell based assay services

April 4, 2012
CenterWatch Staff

Intertek, a quality and safety solutions provider, has launched cGMP compliant cell based assay services for biologic therapeutics in its European Centre of Excellence for Biopharmaceuticals at Manchester, U.K.

“With the addition of tailored cell based assays, Intertek now offers a comprehensive characterization service for biologic therapeutics,” said Ashleigh Wake, biotechnology team leader, Intertek.

The assays determine biological activity or potency by measuring the product’s physiological response and are important to product release and stability studies. They are applied in the analysis of biologics, biosimilars and a wide range of macromolecules including peptides, recombinant proteins, monoclonal antibodies, growth factors, hormones or cytokines.

“We will work with our clients to provide a fully validated cell based assay suitable for regulatory submission, one which performs reproducibly throughout the entire drug development process,” added Wake.

Cell based assay services from Intertek include method transfer, development and validation, release and stability testing, tracking and trending (for establishment and maintenance of assays for earliest identification of assay drift, ensuring reliable results over the assay’s lifetime) and end-point analysis.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing